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INTRODUCTION
Intestinal lymphangiectasia is a relatively rare disorder char-
acterized by dilated intestinal submucosal lymphatics with a
loss of lymph into the bowel lumen (1). It has a clinical impor-
tance in that hypoproteinemia, edema, lymphopenia, and
hypogammagloblinemia can be frequently associated. It is
classified into two groups according to its causes; primary
type (idiopathic), which has no particular causes, and secondary
type, which has underlying causes (2). In Korea, only two cases
of intestinal lymphangiectasia have been reported in Korean
literatures (3, 4). So far, to our knowledge, there are no reports
of intestinal lymphangiectasia associated with cirrhotic ascites.
Until now, there is no specific treatment of proteining-los-
ing enteropathy from intestinal lymphangiectasia. However,
Bac et al. (5) reported that octreotide was effective in one
patient with the condition. Here we report a case of protein-
losing enteropathy induced by intestinal lymphangiectasia
in liver cirrhosis patient who was successfully treated with
octreotide with a review of the literature.
CASE REPORT
A 47-yr-old male patient was admitted to our hospital with
complaints of abdominal pain and diarrhea. Nine years before
the admission he had been diagnosed as chronic hepatitis B
virus infection, and eight months before admission, he had
been diagnosed as liver cirrhosis, but he received no specific
treatment. On admission, he complained of diffuse abdominal
cramping pain and watery diarrhea. His blood pressure was
100/50 mmHg; heart rate 72 beats/min; respiratory rate 24
breaths/min; and body temperature 38.4℃. He showed an
acutely-ill appearance. Physical examination showed mild
abdominal distention, diffuse abdominal tenderness, but no
rebound tenderness. Laboratory findings were as follows: WBC
2,700/ L (lymphocyte 810/ L), Hb 9.1 g/dL, platelet 53,000/
L, ESR 24 mm/hr, total protein 3.9 g/dL, albumin 2.3 g/dL,
total cholesterol 94 mg/dL, ALT/AST 16/57 IU/dL, total
bilirubin 1.2 mg/dL, creatinine 1.1 mg/dL, prothrombin time
65%, HBsAg positive, HBsAb negative, HBeAg negative,
HBeAb positive, and normal urine analysis. Serum immuno-
globulin levels included a normal IgA level of 246 mg/dL
(82-453 mg/dL), a normal IgM level of 107 mg/dL (46-304
mg/dL), and a low IgG level of 537 mg/dL (751-1,560 mg/
dL). Ascites showed yellowish color and analysis showed WBC
1,300/ L (neutrophil 75%), albumin 0.2 g/dL, triglyceride 8
mg/dL and LDH 36 U/L. Chest radiography finding showed
right pleural effusion. Simple abdomen showed mild para-
lytic ileus. Abdominal ultrasonography showed moderate
splenomegaly, ascites, and liver cirrhosis. Cardiovascular assess-
ment showed no signs of pericarditis or valvular abnormali-
ties. Therefore, we diagnosed the patient as having a sponta-
neous bacterial peritonitis associated with liver cirrhosis and
started antibiotics therapy, diuretics, and albumin supply.
Notwithstanding daily continuous albumin infusion, hypoal-
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Successful Treatment of Protein-Losing Enteropathy Induced by
Intestinal Lymphangiectasia in a Liver Cirrhosis Patient with Octreotide
: A Case Report
A 47-yr-old man with hepatitis B virus associated liver cirrhosis was admitted to our
hospital with diarrhea and generalized edema and diagnosed as protein-losing en-
teropathy due to intestinal lymphangiectasia by intestinal biopsy and 
99mTc albumin
scan. During hospitalization, he received subcutaneous octreotide therapy. After 2
weeks of octreotide therapy, follow-up albumin scan showed no albumin leakage,
and the serum albumin level was sustained. We speculate that liver cirrhosis can
be a cause of intestinal lymphangiectasia and administration of octreotide should
be considered for patients with intestinal lymphangiectasia whose clinical and bio-
chemical abnormalities do not respond to a low-fat diet.
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buminemia was sustained. So we suspected that another caus-
es of hypoalbuminemia might be present and started relevant
investigation. With a suspicion of protein-losing enteropathy,
albumin scan was performed. It showed protein-losing at je-
junum after 2 hr of injection and subsequently moved distal
jejunum, ileum, and colon (Fig. 1). In addition,  1 anti-trypsin
clearance was increased at 50.03 mL/day (nomal <30 mL/day).
Small bowel series and colonocopy showed a nonspecific find-
ing. Then we performed duodenoscopy for the inspection of
the suspected lesion on albumin scan. Duodenoscopy showed
serosanguinous exudates in the duodenal mucosa, mucosal
erosion, snow flake appearances, and erythema in the duode-
nal third portion (Fig. 2). Histological examination of a biopsy
specimen from the duodenum showed markedly dilated lym-
phatics in the lamina propria (Fig. 3). Based on the microscopic
findings, we could make a diagnosis of protein-losing enteropa-
Fig. 1. Albumin scan shows protein-losing at the jejunum level after
2 hr of injection and subsequently moved distal jejunum, ileum, and
colon.
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Fig. 2. Duodenoscopy shows serosanguinous exudates in the duo-
denal mucosa, mucosal erosion, and erythema in the duodenal
3rd portion.
Fig. 3. Histological examination of a biopsy from the duodenum. (A) None the markedly dilated lymphatics in the lamina propria (H&E stain,
×100). (B) The dilated lymphatics are more clearly shown (H&E stain, ×200). 
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thy induced by intestinal lymphangiectasia.
Since clinical and chemical abnormalities did not respond
to low-fat diet, on the 24th day of hospitalization, we started
subcutaneous octreotide therapy on the patient (0.1 mg three
times daily). After two weeks of octreotide therapy, follow-up
albumin scan showed no albumin leakage for three hours after
injection. After octreotide therapy, the serum albumin level
increased from 2.2 g/dL to 2.7 g/dL after 50 g albumin infu-
sion. It was consistent with the albumin scan finding. Dur-
ing octreotide therapy, the serum albumin level was maintained
at 2.8 g/dL without albumin infusion. During follow-up, we
stopped octreotide therapy for economic problem of the pati-
ent. After one month, the serum albumin level decreased to
1.9 g/dL with continuous albumin infusion and the patient’s
symptoms recurred with exacerbation of laboratory findings.
So the octreotide therapy was resumed. After initiation of
octreotide therapy, the serum albumin level increased with
time. Until now his serum albumin level has maintained, and
there have been no apparent adverse effects from octreotide
treatment.
DISCUSSION
Intestinal lymphangiectasia is characterized by obstruction
of the intestinal lymphatics, and the increased lymphatic pres-
sure can cause protein-losing enteropathy and malabsorption.
Intestinal lymphangiectasia is a primary disorder in cases of
malformation of lymphatic vessels at the intestinal level or in
other areas of the body. It can also occur secondary to diseases
that may cause intestinal lymphatic obstruction, for example,
abdominal or retroperitoneal fibrosis (6). The most common
causes of secondary intestinal lymphangiectasia are cardiac
diseases and chemotherapeutic, infectious, or toxic substances
that are associated with inflammatory processes that may cause
retroperitoneal lymph node enlargement. Therefore, all of
above condition should be included as a differential diagno-
sis in intestinal lymphangiectasia. None of these conditions
were present in our patient. However, CT or lymphangiogram
may be needed in our case to exclude other possible condi-
tions. Intestinal lymphangiectasia primarily affects children
and young adults. It usually presents with features of a pro-
tein-losing enteropathy; diarrhea, edema, and hypoalbumin-
emia. Chyluria, chylothorax, chylous ascites, lymphocytopenia
and hypocalcemia have also been recognized (7, 11). Endo-
scopic findings of intestinal lymphangiectasia include a scat-
tered snowflake-like lesion in the mucosa (8). Our case showed
a similar snowflake appearance on endoscopy. Consumption
of a high-fat meal during the evening before endoscopic eval-
uation may make these findings more apparent. The diagno-
sis of intestinal lymphangiectasia is generally established by
a biopsy of the intestinal mucosa, which demonstrates dilat-
ed mucosal and submucosal lymphatic channels. Because the
lesions are frequently patchy, multiple biopsies may be nec-
essary to demonstrate the lymphatic lesion. A low-fat diet
with medium-chain triglycerides has been recommended as
the initial management of intestinal lymphagiectasia (7). How-
ever, the patient’s compliance to low-fat diets is not always
good, and refractory cases are occasionally observed with low-
fat diet. So several intervention strategies have been reported
to date, such as corticosteroid, antiplasmin therapy, cytotoxic
drug, and even surgery, but the results have not been satisfac-
tory (5, 9). And there are some reports that protein-losing
enteropathy due to portal hypertension may be improved by
placement of a transjugular intrahepatic portosystemic shunt
(11, 13).
Octreotide is a long-acting somatostatin analog that has
been shown to suppress gastrointestinal motility and hormone
secretion in the pituitary gland, pancreas, and intestine. It also
reduces the splanchnic blood flow, decreases endogenous fluid
secretion in the jejunum, reduces lymph fluid excretion, and
inhibits the absorption of triglycerides (10). There have been
only three patients who were treated with octreotide for pro-
tein-losing enteropathy from intestinal lymphangiectasia (2,
5, 7). The mechanism of action of octreotide in intestinal lym-
phangiectasia involves reduction of intestinal blood flow, inhi-
bition of triglyceride absorption, and reduction of lymph flow.
The true impact of somatostatin and octreotide on portal
hemodynamics remains controversial, and variable changes in
portal pressure and intravariceal pressure in response to these
drugs have been reported in different studies (14, 15). So, in
our case such as intestinal lymphagiectasia combined with
portal hypertension, octreotide may effect on portal pressure
and therefore improve protein losing. The clinical character-
istics in these cases are summarized in Table 1. All of three
cases including our case show the efficacy of octreotide in in-
References (year)
Sex/Age
(yr)
Type Main symptom
Initial albumin
level
Dosage and route of
administration octreotide
Maximal
dose
Maintenance
Bac et al. (5) 1995 M/38 Secondary Anasarca 0.1 mg twice/day SQ
Ballinger et al. (7) 1998 F/17 Primary Edema 1.5 g/dL 0.05 mg three times SQ 0.2 mg twice Yes
Kuroiwa et al. (2) 2001 M/21 Primary Generalized edema,  2.2 g/dL 0.05 mg twice/day SQ 0.15 mg twice Yes
diarrhea
Present case 2004 M/47 Secondary Diarrhea, edema 2.2 g/dL 0.1 mg three times SQ Yes
Table 1. Cases of intestinal lymphangiectasia treated with octreotide in the literature
*SQ: subcutaneous.Protein-Losing Enteropathy treated with Octreotide in a Liver Cirrhosis Patient 469
testinal lymphangiectasia, however, long-term administration
of octreotide seems to be required. No adverse effects have been
documented in octreotide treatment.
To our knowledge there have been no previous reports of
intestinal lymphangiectasia associated with cirrhotic ascites.
We think that the lesion in our patient had been acquired
from impaired lymph flow, considering the late onset of dis-
ease and the fact that the lymphangiectasia appeared to be
associated with liver cirrhosis, a disease known to alter lymph
flow. Thus we think that intestinal lymphangiectasia should
be suspected as a differential diagnosis in refractory hypoal-
buminemia in liver cirrhosis patients.
There are several important aspects in our case. First, it is
the first case of intestinal lymphangiectasia developing in liver
cirrhosis patient. We speculate that liver cirrhosis can be a
cause of intestinal lymphangiectasia though the previous men-
tioned mechanism. Second, through it is a relatively rare dis-
ease, we should consider intestinal lymphangiectasia as a dif-
ferential diagnosis in a patient with protein-losing enteropa-
thy. Third, when we experience continuous hypoalbuminemia
despite albumin infusion in a liver cirrhosis patient, we should
suspect that presence of another cause of hypo-albuminemia.
Although there can be an economic problem and side effects
of long-term therapy of octreotide, the administration of oc-
treotide should be considered for patients with intestinal lym-
phangiectasia whose clinical and biochemical abnormalities
do not respond to a low-fat diet. The mechanism of action
is not entirely clear but appears to involve reduction in gut
protein loss. Further investigation on the mechanism of action
of octreotide is needed. And more fundamental strategies
should be introduced in the management of intestinal lym-
phangiectasia.
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